OPC-415

TERMINATED · PHASE1, PHASE2 · Multiple Myeloma (MM)

This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.